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Background: The TET family of dioxygenases catalyze conversion of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine
(5hmC), but their involvement in establishing normal 5mC patterns during mammalian development and their contributions
to aberrant control of 5mC during cellular transformation remain largely unknown. We depleted TET1, TET2, and TET3
in a pluripotent embryonic carcinoma cell model and examined the impact on genome-wide 5mC, 5hmC, and
transcriptional patterns.
Results: TET1 depletion yields widespread reduction of 5hmC, while depletion of TET2 and TET3 reduces 5hmC at a
subset of TET1 targets suggesting functional co-dependence. TET2 or TET3 depletion also causes increased 5hmC,
suggesting these proteins play a major role in 5hmC removal. All TETs prevent hypermethylation throughout the
genome, a finding dramatically illustrated in CpG island shores, where TET depletion results in prolific hypermethylation.
Surprisingly, TETs also promote methylation, as hypomethylation was associated with 5hmC reduction. TET function is
highly specific to chromatin environment: 5hmC maintenance by all TETs occurs at polycomb-marked chromatin and
genes expressed at moderate levels; 5hmC removal by TET2 is associated with highly transcribed genes enriched for
H3K4me3 and H3K36me3. Importantly, genes prone to hypermethylation in cancer become depleted of 5hmC with
TET deficiency, suggesting that TETs normally promote 5hmC at these loci. Finally, all three TETs, but especially TET2,
are required for 5hmC enrichment at enhancers, a condition necessary for expression of adjacent genes.
Conclusions: These results provide novel insight into the division of labor among TET proteins and reveal important
connections between TET activity, the chromatin landscape, and gene expression.Background
Vertebrate cellular identity arises through intricate diffe-
rentiation events orchestrated by epigenetic regulation of
gene expression. One key epigenetic mechanism is methy-
lation of DNA. DNA is covalently modified by methyla-
tion of the carbon-5 position within cytosine nucleotides
(5mC), an epigenetic mark that, when occurring in gene
promoters, is associated with transcriptional repression.
DNA methylation primarily occurs in the context of
cytosine followed by guanine (CpG), and normal CpG
methylation patterns have been extensively characterized* Correspondence: robertson.keith@mayo.edu
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unless otherwise stated.in human cells [1,2]. Throughout the human genome,
CpG dinucleotides tend to be methylated, except in GC-
dense CpG islands (CGIs) [3-6]. For transcriptionally
active genes, promoter CGIs remain unmethylated
whereas intragenic domains and repetitive sequences are
enriched for CpG methylation, a state that promotes gen-
omic stability. These patterns are reversed in the cancer
genome, which exhibits widespread hypomethylation and
aberrant promoter CGI hypermethylation resulting in
transcriptional silencing. CGI 'shores', defined as 2 kb
regions that flank CGIs, also bear important epigenetic
regulatory function in that they exhibit tissue-specific
differential methylation that appears to regulate gene
expression [7]. Furthermore, cancer genomes lose these
tissue-specific patterns of CGI shore methylation, becomingtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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normal tissue [7].
The DNA methyltransferases (DNMTs) function in the
establishment and maintenance of CpG methylation
patterns. DNMT1, the 'maintenance' methyltransferase,
recognizes hemi-methylated DNA for proper replication
of methylation upon nascent DNA strand synthesis [8,9].
DNMT3A and DNMT3B are 'de novo' methyltransferases,
which establish new methylation patterns, especially
during cellular differentiation [10-12]. Recently, the Ten-
eleven translocation (TET) family of dioxygenases, TET1,
TET2, and TET3, were discovered for their capacity to
modulate DNA methylation patterns. The TET hydroxy-
lases catalyze the conversion of 5-methylcytosine (5mC)
to 5-hydroxymethylcytosine (5hmC) in an α-ketoglutarate-
and Fe(II)-dependent manner [13,14]. In the process
of demethylating DNA, TET enzymes further act on
5hmC to generate 5-formylcytosine and 5-carboxylcyto-
sine (5caC), both of which can be removed by thymine
DNA glycosylase via base excision repair [15-17]. The
hydroxymethyl modification of cytosine is, however, not a
rare or transient modification in the mammalian genome,
with 5hmC comprising an estimated 0.6%, 0.2%, and
0.03% of total nucleotides in mouse Purkinje cells, granule
neurons, and embryonic stem cells (ESCs), respectively
[13,18]. This suggests that 5hmC is a stable mark, rather
than a transient intermediate of cytosine demethylation.
In support of this, specific genomic regions, particularly
gene promoters, enhancers, and exons, are enriched for
5hmC [19-26], and binding of 5hmC by cell-specific
binding partners (for example, the MBD3/NURD complex
and MeCP2) shapes chromatin structure and gene expres-
sion [27-29]. Thus, if 5hmC is a stable, functional mark of
the epigenome, how do the three TET proteins contribute
to the patterning of 5hmC and 5mC and what is the role
of this process in cancer initiation and progression?
TET1 and TET2 have been implicated in establishment
and maintenance of ESC pluripotency and demethylation
of the genome during somatic cell reprogramming [14,30].
Genetic disruption of Tet1 in mouse ESCs skews differen-
tiation toward extraembryonic lineages, but mice with a
deficiency of Tet1 and/or Tet2 are viable, likely due to
functional redundancy with Tet3 [30-32]. Tet3 conditional
null zygotes develop to term, but neonates die postnatally
at day 1 [33]. In the mouse, Tet3 is responsible for global
demethylation of the male pronucleus and for zygotic
epigenetic reprogramming [33-35]. Tet2 and Tet3 are also
largely responsible for enrichment of 5hmC at neuro-
developmental genes during vertebrate neurogenesis, and
in Xenopus, Tet3 is essential for expression of a set of eye
developmental genes and for expression of neuronal and
neural crest markers [36,37]. Taken together, the TET
proteins are clearly important regulators of developmental
gene expression programs and in defining normal cellidentity, albeit with unique and distinct functions for each
family member, which have yet to be fully characterized.
The differential functions for TET family members are
also apparent in the distinct outcomes of TET mutations
in human disease. Catalytic mutations in TET2, but not
TET1, are commonly identified in patients with hema-
topoietic disorders and malignancies such as myelo-
dysplastic syndrome, myeloproliferative neoplasms, acute
myelogenous leukemia, chronic myelomonocytic leuke-
mia, and B-cell and T-cell lymphomas [38-42]. Common
among TET family members is the finding that TET1,
TET2, or TET3 mRNA and 5hmC levels are reduced
across a broad spectrum of solid tumors [43-46]. Despite
the revelation of widespread TET mutations and deregu-
lated TET expression in human cancer, the effect on 5mC
in these malignancies is still debated, as Ko et al. [47] and
Figueroa et al. [48] observed conflicting results of 5mC
changes in TET2 mutant acute myelogenous leukemias.
Likewise, our knowledge of the gene targets of TET cata-
lytic activity is still limited. Collectively, these deficiencies
hamper our understanding of the role of the TETs and
5hmC in tumor initiation and progression. In this study
we systematically identify the epigenetic targets and deter-
mine the genome-wide 5mC and 5hmC patterning acti-
vities of each TET family member in human embryonic
carcinoma cells by specifically depleting each TET family
member using small interfering RNA (siRNA). Genes and
CGIs targeted for 5hmC maintenance by TET1, TET2,
and TET3 overlap extensively among the three family
members, with TET1 targeting the most loci. TET1 exerts
greater influence at high CpG density promoters (HCPs),
while TET2 functions more prominently at low CpG
density promoters (LCPs). These results reveal that TET2
and TET3 actively eliminate 5hmC, particularly in introns
of highly expressed genes. The differential functions of
TETs in promoting or removing 5hmC are chromatin
modification specific: TET1, TET2, and TET3 enrich
5hmC at polycomb-marked H3K27me3 (histone H3 lysine
27 trimethylation) and H2AK119ub (histone H2A lysine
119 monoubiquitination) promoters and genes with mo-
derate expression; TET2 targets H3K4me3-rich promoters
and highly active genes for 5hmC removal. Depletion of
the TETs resulted in large-scale hypermethylation chan-
ges, particularly within promoters and CGI shores, but
TET depletion also more frequently caused hypomethyla-
tion changes of smaller magnitude in promoters and CGIs,
implicating TETs in removing and promoting methylation.
Importantly, enhancer enrichment of 5hmC is mediated by
all three TETs and is required to promote gene expression.
This study yields a comprehensive genome-wide view of
TET-targeted loci in human cancer cells, revealing for the
first time loci that are particularly susceptible to TET-
regulated cytosine modifications and identification of dis-
tinct and overlapping functions of TET1, TET2, and TET3.
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5hmC enrichment is associated with robust gene
activation during cellular differentiation
We chose to study TET function in the human embryonic
carcinoma cell (ECC) line NCCIT, which is a nonsemino-
matous germ cell-derived teratoma. The NCCIT expres-
sion profile resembles that of human ESCs, and NCCIT
can be induced to differentiate with retinoic acid (RA)
treatment into the primary embryonic germ layers and
extra embryonic lineages [49]. Thus, results from this
model system are potentially applicable to both ESC and
cancer cell biology and to the process of differentiation.
Since ECCs are less well characterized in terms of their
5hmC profile than ESCs, we compared NCCIT 5hmC and
TET expression levels to other well-characterized cell/
tissue types. Quantification revealed that ECCs have a
5hmC level close to that of undifferentiated human ESCs
(Figure S1A in Additional file 1). NCCIT 5hmC levels are
above those of an established glioma tumor cell line and
well below those of normal human brain. TET expression
was also examined in the same samples and showed that
TET RNA levels tended to be highest in normal human
brain, although there was not a perfect correlation be-
tween total 5hmC level and TET expression (Figure S1B
in Additional file 1). These findings are consistent with
other published studies [43]. To characterize 5hmC
patterns in pluripotent NCCIT ECCs (UD = undifferen-
tiated) and NCCIT cells differentiated with RA for 7 days
(DF = differentiated), 5hmC residues were labeled with
UDP-azide-glucose and biotin for affinity purification of
5hmC-containing genomic DNA fragments, followed by
deep-sequencing of the 5hmC-modified DNA [50]. UD
cells displayed 5hmC enrichment in gene promoters,
as described for pluripotent human ESCs [51] [GEO:
GSM747152]. Likewise, peaks of 5hmC enrichment occu-
pied many of the same genomic loci in UD and H1 ESCs
(P < 0.0001; Figure 1A) [52], reinforcing the notion that
ECCs represent relevant models for ESCs and differenti-
ation. Some promoter 5hmC enrichment (approximately
25%), however, was unique to each cell type. UD ECCs
uniquely exhibited 5hmC enrichment at genes involved in
neuronal differentiation and cellular morphogenesis, but
lacked 5hmC enrichment at genes involved in ion trans-
port and nucleotide metabolism (Figure S1C in Additional
file 1). These differences could be attributable to differing
cell of origin, degree of pluripotency, or the transformed
state of the ECCs. Further validation with an independent
5hmC pull-down experiment coupled with quantitative
PCR (qPCR) confirmed the NCCIT UD 5hmC-seq enrich-
ment results at several loci (Figure S2 in Additional file 1).
HOXD10, HOXC5, and EVX2 promoters had abundant
5hmC, HES7 and HAND1 promoters exhibited low
5hmC levels, and the NANOG locus was devoid of 5hmC
(Figure S2 in Additional file 1). In general, 5hmCaccumulates in peaks flanking the TSS (transcription start
site) of UD promoters (Figure 1B). Based on previously
published 5mC-seq data from our laboratory in this same
system [1], 5mC shows some promoter enrichment but is
more abundant across the gene body toward the 3’ UTR,
whereas 5hmC is relatively low throughout the gene body
except near the 3’ UTR, where it shows a low level of
accumulation (Figure 1B). This is in contrast to mouse
ESCs in which 5hmC increases across the gene body away
from the promoter [19,20]. Exons, however, display enrich-
ment of 5hmC that is inversely proportional to promoter
CpG density (Figure 1C). DF cells show similar patterns,
albeit with lower levels, of 5hmC enrichment as observed
in the UD state (Figure 1B). In CGIs, 5hmC density is
defined by genomic location: promoter and intragenic CGIs
show low levels of 5hmC, whereas gene body CGIs are
5hmC-rich (Figure 1D). Strikingly, a sharp peak of 5hmC
marks the border between CGIs and CGI shores (Figure 1D).
In general, 5hmC in human ECCs exhibits a distribution
profile that is specific to genetic features.
Notably, most genes (approximately 80% with 5hmC
changes) show a decrease of 5hmC upon induction of
differentiation, but a discrete subset gain 5hmC across
promoters and gene bodies based on 5hmC enrichment
and deep sequencing (Figure 1E). This is consistent with
the overall levels of 5hmC, which decline during NCCIT
differentiation, accompanied by modest changes in TET
expression. During an extended timecourse of RA-
induced NCCIT differentiation, some global reduction
in 5hmC was observed at day 7, the timepoint analyzed
here, and 5hmC continued to decline as differentiation
proceeded (Figure S1A,B in Additional file 1). Several of
these changes, identified through deep sequencing, were
examined at base-pair resolution by TET-assisted bisul-
fite conversion (TAB) coupled with Sanger sequencing
[25], confirming the overall trends illustrated by the
5hmC-seq results (Figure S3A in Additional file 1). The
TAB-seq results reiterate the estimate by Yu et al. [25]
that 5hmC comprises a low amount (estimated to be 3
to 4%) of total intragenic cytosines. Expression micro-
arrays were used to identify relationships between 5hmC
and expression upon induction of the differentiation
program. Genes that gain 5hmC in DF cells are
significantly (P < 0.0001) prone to activation upon diffe-
rentiation and are enriched for genes involved in pat-
terning and differentiation of ectodermal derivatives (for
example, hindbrain, nerve, and epithelium development)
(Figure 1F,G). Genes with 5hmC depletion after differen-
tiation showed a slight (but not significant: P = 0.1419)
trend toward downregulated expression. 5hmC-depleted
genes can be classified into two subsets: those with
variable loss and/or redistribution of 5hmC and genes with
complete loss of 5hmC (Figure 1H; Figure S4 in Additional
file 1). Together, these data suggest that 5hmC is enriched
Figure 1 Characterization of 5hmC patterns in undifferentiated and retinoic acid differentiated NCCIT embryonic carcinoma cells.
(A) Promoters, CGIs, and genes with peaks of 5hmC in UD NCCIT human ECCs (hECC) and H1 human ESCs (hESC) were compared. Numbers represent
features common between or exclusive to UD hECCs and H1 hESCs. Overlapping sets in all three features were statistically significant (P < 0.0001).
(B) Log2 tag density of 5hmC- and 5mC-sequencing in UD and DF cells from -5 to +5 kb across promoters, across gene bodies (represented as a
percentage from 25% to 75%) and -5 to +5 kb across the TSS. Dotted lines represent TSS, +5 kb from TSS/25% of gene body, 75% of gene body/-5 kb
from transcription termination site (TTS), and TTS. (C) 5hmC tag density across exons with high (HCP), intermediate (ICP), and low (LCP) CpG density
promoters and (D) across CGIs in promoters, gene bodies, and intergenic regions. (E) Number of gene promoters and gene bodies with differential
5hmC upon RA differentiation of NCCIT cells. (F) Promoters and gene bodies with elevated 5hmC in DF cells were compared to genes whose
expression increased upon differentiation. Blue and yellow bars represent overlapping genes with differential 5hmC and increased expression (shown
as a percentage of upregulated genes); the grey bar represents the percentage of all differentiation-upregulated genes in the genome. Transcriptionally
upregulated genes with gain of 5hmC are significantly overrepresented (*P < 0.0001). (G) Ontology analysis of upregulated genes with increased
5hmC enrichment. (H) Examples of the three types of 5hmC changes observed in DF cells: (i) increased 5hmC; (ii) partial loss and redistribution of
5hmC; and (iii) total or near complete loss of 5hmC.
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potentially contributing to a poised chromatin state.
Roles for TET1, TET2, and TET3 in patterning
methylcytosine across intragenic regions
NCCIT ECCs serve as a model for understanding the
function of TET dioxygenases in patterning the methy-
lome because all three TET enzymes are abundantly
expressed. TET3 expression is about 1.7-fold that of
TET2, and TET1 is the most abundant of the three TETs,
with about 30-fold the expression of TET2, a ratio similar
to that observed in human ESCs (Figure S1B, right panel
in Additional file 1). To investigate their functions, we
depleted TET1, TET2, and TET3 by siRNA transfection in
UD NCCIT cells. This method generates transient, acute
depletion of each TET, allowing us to observe the most
immediate, direct epigenetic effects of the functional de-
pletion and avoiding potential compensatory changes that
have been shown to occur with other methods such as
transgenic small hairpin RNA or gene knockouts [53,54].
A non-targeting control (NTC) siRNA was utilized for
comparison. Transcript levels for TET1, TET2, and TET3
were depleted by 60 to 70% over 72 hours (Figure S5 in
Additional file 1). No phenotypic changes were observed
in siTET-treated cells relative to siNTC-treated cells du-
ring the 72 hour experiment (not shown). These de-
pletions had little effect on the transcript abundance
of DNMT1, DNMT3A, or DNMT3B or of the other
TETs. Likewise, transcription of the housekeeping genes
TUBA1C, DYNLL, and RPL30 was unaffected, showing no
off-target effects and no defects in major cell processes or
viability. Since 5hmC abundance was loosely connected
with gene expression during differentiation in NCCIT, we
asked whether TET1, TET2, or TET3 regulate the expres-
sion of pluripotency or differentiation markers. Depletion
of TET transcripts did not impact lineage marker expres-
sion, except for the trophectodermal marker HAND1
(Figure S5 in Additional file 1). This result is consistent
with prior studies in Tet1-deficient mouse ESCs that
showed skewing toward trophectodermal fate [14,30,31].
To determine the impact of TET depletion, total levels of
5mC and 5hmC were assayed with 5mC- and 5hmC-
specific antibodies in an ELISA-like detection assay. The
genomic abundance of 5mC was not significantly affected
by TET depletion (although there was a trend toward
hypermethylation in TET2 and TET3 depletions; Figure
S6 in Additional file 1). siTET1 cells showed approxi-
mately 60% loss of 5hmC, but siTET2 and siTET3 did not
significantly impact total 5hmC (Figure S6 in Additional
file 1). Thus, do each of the TETs have region-specific or
site-specific impacts on 5hmC and 5mC?
5hmC-seq and 5mC-seq were performed on siTET1-,
siTET2-, and siTET3-treated cells to determine the
specific roles of each TET on patterning the epigenome.Scatter plots were used to compare levels of 5hmC and
5mC peaks between siTET- and siNTC-treated cells
(Figure S7A,B in Additional file 1). siTET cells had peaks
with both lower and higher 5hmC levels relative to
siNTC. All siTET knockdowns, but particularly siTET1,
caused robust hypermethylation at sites with low to
moderate basal 5mC levels (red arrow in Figure S7B in
Additional file 1). This comparison also revealed some
hypomethylation at sites with high basal methylation in
siTET1 (green arrow in Figure S7B in Additional file 1).
5mC tag density across gene bodies shows a subtle
increase in response to TET depletion, with siTET1
yielding the most hypermethylation (Figure 2A). Pro-
moter distribution of 5hmC and 5mC is CpG density-
dependent, with HCPs displaying low 5hmC and 5mC
levels and LCPs being enriched for 5hmC and 5mC
(Figure 2A). In 5hmC-rich promoters, exons, and 3’
UTRs, depletion of any of the TETs induced a general
loss of 5hmC (Figure 2A). Reductions in 5hmC in the
promoter were CpG density-dependent as noted by the
5hmC tag densities surrounding the TSS; siTET1-treated
cells showed the greatest reduction of 5hmC at HCPs,
whereas siTET2-treated cells displayed the greatest
reduction of 5hmC at LCPs. 5hmC loss in exons was
abundant in all siTET depletions, with siTET1 and
siTET2 showing the least and most reduction in 5hmC,
respectively (Figure 2A).
Peaks of differential 5hmC and 5mC across intragenic re-
gions were used to assess the site-specific epigenetic effects
of each TET depletion [55]. Genes with at least two-fold
increase or decrease within promoters, UTRs, exons,
introns, and regions 1 kb downstream of the transcription
termination site (TTS) were counted (Figure 2B; Figure
S7C in Additional file 1). siTET1 yielded predominantly
hypo-hydroxymethylation. siTET2 and siTET3 cells deve-
loped loci with both hypo- and hyper-hydroxymethylation.
Notably, in siTET2, intragenic regions tended to lose
5hmC, except introns. This effect was even more apparent
when 5hmC changes were stratified by magnitude. Introns
most affected by siTET2 and siTET3 (more than four-fold
5hmC changes) gained 5hmC (Figure S8A in Additional
file 1). Select loci predicted to lose 5hmC based on the
sequencing data were confirmed by independent 5hmC
pull-down coupled with qPCR (Figure S9 in Additional
file 1). Analysis of differential 5mC peaks confirmed our
earlier observation (Figure S7B in Additional file 1) that
both hypermethylation and hypomethylation result from
siTET depletion (Figure S8B in Additional file 1). In-
triguingly, the most robust (more than four-fold) 5mC
changes were hypermethylation events. Numerous smaller
5mC changes of less than four-fold were most frequently
hypomethylation events (Figure S8B in Additional file 1;
Additional file 2). Thus, depletion of TET1, TET2, or
TET3 caused hypomethylation events of small magnitude
Figure 2 (See legend on next page.)
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Figure 2 Depletion of TET1, TET2, or TET3 causes genome-wide loss of 5hmC and both DNA hypomethylation and hypermethylation.
(A) Tag density plots of 5mC (dashed line plots) and 5hmC (solid line plots) from -5 to +5 kb across gene promoters, across gene bodies (25 to
75%), and from -5 to +5 kb across the transcription termination site (TTS) (left panels). Tag density plots were also drawn for exons across HCP,
intermediate CpG density promoter (ICP), and LCP genes (right panels). (B) Pie charts for genes with decreased (top) and increased (bottom)
5hmC. Pie pieces represent total number of genes with two-fold or greater 5hmC change in the specified gene region. (C) Area proportional
Venn diagrams illustrating overlap of promoters that lose 5hmC and gain or lose 5mC in each TET knockdown. P < 0.0001 except for overlap
of TET3 hypohydroxymethylation with siTET3 hypermethylation for which P = 0.0009. (D) Tag density of 5mC (left) and 5hmC (right) for only
promoters with (i) more than two-fold reduction of 5hmC in siTET1, (ii) more than two-fold reduction of 5mC in all siTET depletion conditions,
and (iii) more than two-fold increase of 5mC in all siTET depletions. The region shown is -3 kb upstream and +3 kb downstream relative to TSS.
Line colors are as in (A). Colored arrows indicate approximately -1 kb and +250 bp positions relative to the TSS. (E) Tag density of 5mC (top) and
5hmC (bottom) across intronic sequences for only genes showing increased 5hmC within introns of siTET2-treated cells.
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hypomethylation and hypermethylation changes were
significantly enriched at loci that lost 5hmC in siTET1,
siTET2, and siTET3 cells (Figure 2C), linking the two
opposing outcomes. These results, taken together with the
results in Figure S6 in Additional file 1 showing no net
gain or loss of total 5mC, suggest that 5hmC depletion in
siTET knockdown cells leads not to global hypermethyla-
tion but instead to a redistribution of global 5mC.
Promoters with decreased 5hmC overlapped exten-
sively among the TET knockdowns (58 to 90% overlap),
showing overlapping function of TET1, TET2, and TET3
at these loci (Figure S10A, left in Additional file 1); TET1
showed the largest number of unique targets with hypo-
hydroxymethylation. 5hmC-depleted promoters in siTET1,
siTET2, or siTET3 cells represented genes with roles in
embryonic development, cell adhesion, motility, and
proliferation (Figure S10B in Additional file 1) and cor-
responded highly with those promoters that lose 5hmC
upon differentiation of NCCIT cells (approximately 60%
of siTET targets overlap with DF-induced 5hmC changes;
P < 0.0001; Figure S10A, right in Additional file 1). Thus,
TET1, TET2, and TET3 co-regulate cytosine modifications
at many of the same target sites, and these co-regulated
targets control embryonic development and basic cellular
physiology. In addition, our results clearly show that nei-
ther DNA hypermethylation nor hypo-hydroxymethylation
is the sole outcome of TET depletion, suggesting that the
role of the TETs in regulating DNA methylation is more
complex than previously thought.
We next asked how loss of 5hmC impacts 5mC distri-
bution around the TSS by plotting the tag density for only
genes with 5hmC loss in siTET1-treated cells. These loci
showed a large trough of 5mC across the TSS, but TET
depletion did not impact the overall 5mC distribution at
these promoters that lose 5hmC (Figure 2D(i)). Similarly,
we plotted the 5mC distribution for subsets of genes that
lose (Figure 2D(ii)) and gain (Figure 2D(iii)) 5mC in all
siTET cells (Figure 2D). Hypomethylated promoters
display peaks of 5mC at -1 kb upstream of the TSS and
immediately downstream of the TSS (Figure 2D(ii),
orange arrows). Hypomethylation at these promoters issubtle and occurs in the immediate vicinity of the TSS
(Figure 2D(ii)), whereas promoter hypermethylation is
much more dramatic and occurs across a >6 kb region
flanking the TSS (Figure 2D(iii)). Hypermethylated pro-
moters also have a peak of 5mC at -1 kb (albeit, not as
pronounced as that in hypomethylated promoters) but
display a distinct depression of 5mC between -250 bp
to +750 bp surrounding the TSS (Figure 2D(iii), blue
arrow). In the siTET-treated cells, the peak of 5mC at -1
kb increases, and the depression across the TSS regains
a peak of 5mC. Thus, the methylation landscape in
promoters is dramatically different for those loci that
become hypomethylated versus those that become
hypermethylated upon TET depletion. Since TET2
depletion resulted in 5hmC enrichment particularly in
introns, we plotted the 5hmC and 5mC tag density for
introns with hyper-5hmC. These genes showed substan-
tial redistribution of 5hmC patterns (Figure 2E). siNTC
and siTET1 introns had low invariable 5hmC across
introns, but siTET2 and to a lesser extent siTET3
showed a striking peak of 5hmC across introns typically
associated with 5hmC depletion in flanking exons.
TET proteins control cytosine modifications at enhancers
and prevent hypermethylation of promoter CGI shores
Previous genome-wide profiling of 5hmC showed that this
mark was enriched at enhancers, although the role of each
TET in mediating this was not examined [24-26]. Using
profiles for acetylation of H3K27 (H3K27ac) in H9 ESCs
as enhancer annotations [56] [GEO:GSM605307], we
examined 5hmC abundance in NCCIT cells. In siNTC-
NCCIT cells 5mC and 5hmC show an inverse enrichment:
5mC is low inside enhancers but enriched at their bound-
aries (Figure 3A, top); 5hmC is strongly enriched within
enhancers but falls at the boundaries forming a sort of
gutter at the enhancer edge (Figure 3A, bottom). TET2
depletion had the greatest impact on average 5hmC at
enhancers (Figure 3A, bottom), but TET1 targets a greater
number of enhancer elements for 5hmC enrichment
(Figure S11 in Additional file 1). 5hmC in enhancers is
mostly depleted in siTET2 and is partially depleted in
siTET1 and siTET3 conditions, indicating involvement of
Figure 3 (See legend on next page.)
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Figure 3 Impact of TET depletion at key regulatory elements. (A) Tag density plots of 5mC (top) and 5hmC (bottom) in enhancer elements
defined by previously published H9 ESC H3K27ac ChIP-seq profiles [GEO: GSM605307]. Red arrow in the bottom panel denotes a trough of 5hmC
at enhancer boundaries that is lost in siTET2/3-treated cells. (B) Box plots of log2 fold-change based on differential SICER analysis of (i) 5hmC and
(ii) 5mC peaks. Fold-change is shown for CGIs and CGI shores and is stratified by changes of greater than four-fold (>4×) and changes between
two-fold and four-fold (2×). (C) Tag density plots of 5hmC and 5mC for CGIs in promoters, gene bodies, and intergenic regions. (D) Bar graph
illustrating the proportion of CGIs and CGI shores in three gene regions that sustain hypermethylation in each TET knockdown. (E) Area proportional
Venn diagrams of CGIs with loss of 5hmC, loss of 5mC, and gain of 5mC under siTET1, siTET2, and siTET3 depletion conditions. (F) Area proportional
Venn diagrams representing CGI shore hypermethylation coinciding with 5hmC gain in siTET2 and 5hmC loss in siTET1 depletion conditions
(P < 0.0001 for both).
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maintaining 5hmC at enhancers. The gutter of 5hmC at
enhancer boundaries in siTET2- and siTET3-treated cells
recedes, resulting in 5hmC accumulation, suggesting that
TET2 and TET3 may help to define enhancer borders
(Figure 3A, red arrow).
CGIs experienced 5hmC depletion in siTET1-, siTET2-,
and siTET3-treated cells, but a large proportion of shores
had elevated 5hmC levels in siTET2- and siTET3-treated
cells (Figure 3B(i); Figure S12A(i) in Additional file 1).
The median 5mC changes in CGIs for siTET1 and siTET2
were hypomethylation (Figure 3B(ii); Figure S12A(ii) in
Additional file 1). This is in stark contrast to CGI shores,
which were robustly hypermethylated in siTET1, siTET2,
and siTET3 cells (Figure 3B(ii)). CGI methylation patterns
occurred irrespective of intragenic versus intergenic loca-
tion (Figure 3C); however CGI shore hypermethylation
was most abundant in shores associated with promoters,
as 26%, 10%, and 11% of gene promoters with CGIs had
hypermethylated shores upon TET1, TET2, and TET3
depletion, respectively (Figure 3D). CGIs that lose 5mC or
5hmC significantly overlap among the TET knockdowns
(Figure 3E; Figure S12B,C in Additional file 1), but analysis
of CGI and CGI shore hypermethylation events reveals
unique targets between TET1 and TET2 (Figure 3E). A
significant proportion of hypermethylated CGI shores in
siTET1 cells had decreased 5hmC (Figure 3F). On the
other hand, CGI shore hypermethylation in siTET2 cells
was associated with increased 5hmC (Figure 3F). TET1
targets promoter CGI shore hypermethylation at genes in-
volved in basic cellular processes such as intracellular
transport, transcription, and cell death (Figure S12D in
Additional file 1). TET2 targets promoter CGI shore
hypermethylation at genes involved in cytoskeletal orga-
nization, cell signal transduction pathways, and morpho-
genesis (Figure S12D in Additional file 1). Thus, again,
TET1 and TET2 demonstrate a functional divergence in
their impact on the epigenome. In summary, TET1, TET2,
and TET3 preferentially remove methylation at CGI
shores, particularly those within promoters, suggesting
that TET activity is heavily influenced by CpG density,
and TET1 and TET2 target separate sets of CGI shores
where they function exclusively of one another in 5mC
removal.Gene body hypomethylation in siTET depletion
conditions is associated with gene repression
To understand how TET depletion impacts gene
expression, microarray analysis was performed for siTET1,
siTET2, and siTET3 depletion and compared to siNTC
under undifferentiated conditions. All three siTET deple-
tions yielded abundant gene activation and repression
events, but gene repression dominated (Figure 4A).
Repressed genes were enriched for a subset of genes that
become transcriptionally activated upon differentiation of
NCCIT cells (Figure 4B). We next examined the relation-
ship between gene expression and epigenetic changes in
NCCIT cells. In previous reports, gene expression and
methylation changes in TET1-depleted mouse ESCs did
not strongly correlate, likely due to TET function inde-
pendent of TET1’s catalytic domain [20]. In our study, a
gene’s basal expression level largely determined the epi-
genetic outcome of siTET depletion. Highly transcription-
ally active genes were significantly prone to increased
5hmC in introns and exons after TET2 or TET3 depletion
(Figure 4C; Figure S13 in Additional file 1). Mode-
rately expressed genes underwent 5hmC depletion under
siTET1 conditions, but transcriptionally silenced/low
expressed genes were excluded from 5hmC changes
(Figure 4C; Figure S13 in Additional file 1). 5hmC changes
in gene promoters, bodies, or associated CGIs were not
associated with gene expression changes (data not shown);
however, when we assessed the impact of 5hmC loss in an
enhancer on its closest neighboring gene (within a 20 kb
limit), there was a significant association with gene repres-
sion, particularly of genes with high basal levels of expres-
sion (Figure 4D). Approximately 20% of gene repression
events under TET depletion conditions were accounted
for by loss of 5hmC in an adjacent enhancer (Figure 4D).
On the other hand, 5hmC increases in enhancers or
gene bodies did not correlate with expression changes
(data not shown). TET1, TET2, and TET3 co-mediated
5hmC enrichment at enhancers regulating expression of
genes involved in cell proliferation, cell motility, and
angiogenesis; TET1- and TET2-mediated 5hmC enrich-
ment impacted genes required for apoptosis (Figure 4E).
In summary, intragenic TET-mediated 5hmC enrich-
ment is impacted by basal expression level, and most
importantly, TET1, TET2, and TET3 drive gene
Figure 4 (See legend on next page.)
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Figure 4 Relationships between gene expression and DNA epigenetic marks. (A) Quantity of upregulated and downregulated genes in siTET1,
siTET2, and siTET3 conditions. (B) NCCIT cell gene expression changes that occur with siTET depletions were compared to gene expression changes
that occur during RA-induced differentiation from UD to DF. Downregulated genes in siTET1, siTET2, and siTET3 depleted cells were significantly
enriched for genes upregulated during differentiation. Shown are the percentages of genes downregulated in siTET conditions that overlap with genes
that become upregulated in DF cells and the percentage of total upregulated genes in DF cells. (C) Hypo- or hyper-5hmC introns of siTET depletions
were compared to basal gene expression levels in UD NCCIT cells. Shown is the percentage of genes with 5hmC changes in introns in siTET-treated cells
that occur in highly, moderately, or lowly expressed genes. These percentages of overlapping genes are compared to the total percentage of highly
(red bar), moderately (gold bar), or lowly (green bar) expressed genes. (D) Area proportional Venn diagrams showing the number of repressed genes
that are in proximity to H3K27ac-marked enhancers that lose 5hmC upon TET depletion (*P < 0.0001; ‡P = 0.0060). (E) Ontology analysis of repressed
genes that lose 5hmC in nearby enhancers in siTET1-, siTET2-, and siTET3-treated cells.
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enhancer elements.
TET functions in cytosine modification at active and
repressed chromatin
We examined how TET1, TET2, and TET3 interface with
epigenetic marks characteristic of different chromatin
domains (that is, active, repressed, or transcriptionally
poised). Our group has previously assessed histone mark
occupancy in UD and DF NCCIT cells [1]. Genes
with H3K4me3, H3K27me3, or H2AK119ub-marked
promoters were compared with those genes that sustain
hypo- and hyper-5hmC events in siTET depletion condi-
tions. H3K27me3- and/or H2AK119ub-marked promoters
tend to lose 5hmC in the absence of TETs, suggesting that
TET1, TET2, and TET3 promote 5hmC accumulation at
these loci (Figure 5A). H3K4me3-monovalent promoters,
which typically lack 5hmC but are occupied by TET1
[20,21], show a propensity for 5hmC accruement in
siTET2-treated cells but are protected from loss of 5hmC
in all TET-depleted cells (Figure 5B). Along these lines, a
significant proportion of genes enriched for H3K36me3 in
exons, a mark of transcriptional activity, undergo hyper-
5hmC in introns of siTET1-, siTET2-, and siTET3-treated
cells (Figure 5B). Together these results indicate that TET
proteins, especially TET2, engage in removing 5hmC from
genes within chromatin marked for transcriptional acti-
vity. Bivalent promoters (containing both H3K4me3 and
H3K27me3), which are 5hmC-rich, lose 5hmC when any
of the TETs are depleted, but a subset of these loci are also
prone to gain 5hmC under TET2- or TET3-depletion
conditions (Figure 5C). Lastly, genes with H3K9me3
marks, which are associated with heterochromatin and
transcriptional silencing and are devoid of 5hmC in
normal cells, were significantly excluded from 5hmC
changes in TET1- and TET2-depleted cells (Figure 5C).
H3K27me3-marked genes that lose 5hmC after siTET1
treatment function in developmental processes such as
patterning and morphogenesis (Figure 5D). H3K4me3-
marked genes with increased 5hmC after siTET2 treatment
drive basic cellular processes such as DNA replication,
RNA processing, and translation (Figure 5E).Hypomethylation and hypermethylation outcomes
were also closely connected with chromatin domains.
H3K27me3-marked promoters and H2AK119ub-marked
promoters were susceptible to hypomethylation upon
TET depletion (Figure S14A in Additional file 1). Intri-
guingly, promoter hypermethylation also tended to occur
at H2AK119ub-marked promoters (but not H3K27me3,
H3K4me3, or bivalent promoters), suggesting that TETs
actively demethylate 5mC at H2AK119ub-marked promo-
ters. H3K4me3-marked promoters were protected from
hypo- and hypermethylation under TET-depletion con-
ditions, and genes marked with exon H3K36me3 were
prone to intragenic hypermethylation (Figure S14B
in Additional file 1). Generally, bivalent promoters and
H3K9me3-marked genes were not targeted for hypo- or
hypermethylation by TET proteins (in fact, H3K9me3-
marked genes were significantly protected from methy-
lation changes; Figure S14C in Additional file 1). In
summary, H3K27me3- and H2K119Aub-marked genes
tend to lose both 5hmC and 5mC when TETs are
depleted. Active H3K4me3- and H3K36me3-marked
genes become enriched for 5hmC in promoters and exons
and become hypermethylated in gene bodies upon TET
depletion. Thus, polycomb-repressed genes and highly
active, H3K4me3/H3K36me3-marked genes exhibit op-
posing epigenetic fates under TET depletion conditions,
and both epigenetic fates impact pathways associated with
cancer phenotypes.
Loss of 5hmC in TET-depleted cells coincides with genes
susceptible to aberrant hypermethylation in cancer
Given that aberrant promoter hypermethylation is a fea-
ture of cancer cells and a popular paradigm of TET func-
tion is to prevent this event [57], we asked whether there
is any link between cancer hypermethylated loci and genes
that sustain 5hmC changes in our TET knockdowns.
Using a recently published list of genes that are frequently
hypermethylated across a wide spectrum of human can-
cers [58], we investigated their relationship with genes that
sustain cytosine modification changes in siTET-treated
cells. Interestingly, genes susceptible to promoter hyper-
methylation in cancer were overrepresented among genes
Figure 5 Relationships between hydroxymethylation changes under TET depletion conditions and histone mark occupancy.
(A-C) Genes with changes in 5hmC after TET depletion were compared to subsets of genes with histone modifications (as marked) mapped
previously in UD NCCIT cells [1]. Shown are the percentage of genes with 5hmC changes that overlap with the given histone modification, and
the percentage of all promoters (or other features) with the given histone modification in the genome (total number of genes = 23,218; total
genes with 5hmC changes per region are as listed in Figure 2B). 5hmC changes that have an overrepresentation or underrepresentation of the
given histone mark are designated: *P < 0.0001 or ‡P < 0.001. (D) Ontology analyses of subsets of H3K27me3-marked genes with loss of 5hmC
after siTET1 treatment and of (E) H3K4me3-marked genes with gain of 5hmC after siTET2 treatment.
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cells (Figure 6A; data not shown). Likewise, siTET2 induced
gain of 5hmC inversely associated with cancer hypermethy-
lation (P = 0.0220; data not shown). Hypermethylation-
susceptible genes with loss of 5hmC in siTET-treated cells
were heavily enriched for processes involved in embryonic
development, including cell fate specification, morphoge-
nesis, and patterning (Figure 6B). In summary, TET1,
TET2, and TET3 are required for maintenance of 5hmC
at genes susceptible to hypermethylation in cancer. We
propose that intragenic 5hmC enrichment (which was
observed at genes robustly activated upon differentiation(Figure 1F)) is lost at highly transcriptionally active genes
(Figure 4C) and polycomb-regulated loci upon TET knock-
down (Figure 5A), permitting 5mC redistribution. 5hmC is
also depleted at genes silenced by aberrant hypermethyla-
tion in cancer upon TET knockdown (Figure 6A). Enrich-
ment of 5hmC at promoters and/or gene bodies may create
a metastable transcriptionally permissive state (neither
highly active nor transcriptionally silent, but capable of a
robust response to stimuli); the metastable state is more
easily perturbed and one consequence of such perturbation
is loss of 5hmC enrichment, which may represent a crucial
precursor to gene silencing by aberrant DNA methylation.
Figure 6 Links between aberrant cancer methylation and TET function. (A) Genes susceptible to hypermethylation in cancer (n = 1,009) [58]
showed significant overlap with those that lose 5hmC within gene bodies (that is, exons and introns) in each of the siTET-treated conditions:
45.7% of hypermethylated genes overlap 5hmC loss in siTET1-treated cells (P = 0.0255); 34.3% of hypermethylated genes overlap 5hmC loss in
siTET2-treated cells (P = 0.0002); 31.0% of hypermethylated genes overlap 5hmC loss in siTET3-treated cells (P = 0.0082; siTET3 not shown).
(B) Ontology analysis of genes susceptible to promoter hypermethylation that also lose 5hmC in siTET-treated cells.
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This study represents the first comprehensive genome-
wide analysis of the role of TET1, TET2, and TET3 in
patterning the distribution of 5mC and 5hmC in human
cancer cells. Depletion of only one TET family member
yielded robust reduction of 5hmC across intragenic re-
gions, enhancers, and CGIs, and many of the same loci
were affected by siTET1, siTET2, or siTET3 depletion
conditions, suggesting a synergistic role for the TETs in
establishment of 5hmC patterns in NCCIT cells. Loci
uniquely affected by depletion of each TET family mem-
ber were also identified. Importantly, our results reveal
that TET2 and TET3, but not TET1, actively eliminate
5hmC throughout the genome, particularly at introns, as
evidenced by hyper-hydroxymethylation in TET2- and
TET3-depleted cells. Thus, our results suggest that allTETs, especially TET1, target loci for hydroxylation of
5mC to 5hmC, but only TET2 and TET3 are responsible
for subsequent removal of 5hmC in the cytosine de-
methylation cascade. TET function in demethylation was
particularly prominent at CGI shores, which became dis-
proportionately hypermethylated relative to CGIs and
surrounding regions. In addition to the role of the TETs
in DNA demethylation, the results of this study unex-
pectedly implicate TETs in promoting DNA methylation,
and show that TET activity is also closely connected
with specific chromatin domains. The finding that TETs
have a role in promoting 5hmC at loci targeted for
aberrant methylation in cancer is consistent with an
overall observation that TET establishment of intragenic
5hmC enrichment is associated with a state of transcrip-
tional permissiveness. Likewise, TET-mediated 5hmC at
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active genes.
One key finding from our results was that genes and
CGIs targeted for 5hmC maintenance by TET1, TET2,
and TET3 overlap extensively among the three family
members, but the impact of each TET on target gene
DNA methylation was CpG density-dependent. Promoter
5hmC levels are inversely correlated with CpG density, as
low CpG density promoters show the most abundant
5hmC in UD NCCIT cells, similar to murine ESCs [23].
Depletion of TET1 had the greatest impact on 5hmC loss
at HCPs, also consistent with results in murine ESCs
where Tet1 was genetically inactivated [59]. TET2 deple-
tion in our system, however, had the greatest impact on
5hmC loss at LCPs, suggesting that TET1 and TET2
function more prominently at HCPs and LCPs, respec-
tively. Such functional divergence between TET1 and
TET2 likely relates to their protein structure. TET1 con-
tains a CXXC zinc finger domain and possesses high
affinity for non-methylated CpG-dense regions [20,60,61],
whereas TET2 lacks this motif, perhaps allowing it to
function more readily at or be specifically targeted to re-
gions of low CpG density.
Reduction of TET2 or TET3 levels caused 5hmC accu-
mulation in many regions of the genome. The simplest
explanation for this observation is that TET2 and TET3
are primarily responsible for the formation of down-
stream cytosine intermediates (that is, 5-formylcytosine
and 5-carboxylcytosine) within the demethylation cas-
cade and disruption of either TET2 or TET3 yields accu-
mulation of 5hmC, although this hypothesis has yet to
be tested directly. An alternative explanation is that
TET2 and TET3 limit each other’s 5mC to 5hmC hy-
droxylation activity. Within gene bodies, 5hmC accumu-
lation was particularly evident in introns. In UD NCCIT
cells, exons are enriched for 5hmC over introns, and
these results suggest a role for TET2 and TET3 in the
removal of 5hmC from introns. The potential impact of
this function on maintaining the rate of transcription,
preventing spurious transcription initiation, or pre-
serving splicing fidelity is intriguing but unknown.
Some promoters targeted by the TETs for establishment
of 5hmC exhibited large-scale DNA hypermethylation
upon siRNA depletion. This is consistent with a study
where Tet1 was depleted in murine ESCs, which resulted
in increased 5mC in a subset of promoters [59]. This
current analysis also includes siTET2 and siTET3, and
reveals that all three TET family members are essential for
promoter demethylation in the cancer genome. Un-
expectedly, we observed that promoter and CGI hypo-
methylation events (of relatively small magnitude) far
outnumbered promoter hypermethylation events (which
tended to be of larger magnitude). As we discuss fur-
ther below, DNA hypomethylation resulting from TETdepletion may be an indirect consequence of reduced
5hmC or the result of TET functions that are separate
from their known catalytic activity on cytosine substrates.
Interestingly, CGI shores showed dramatic hypermethyla-
tion upon TET knockdown, especially for siTET1, and this
was particularly evident for CGIs in promoters (Figure 7A).
CGIs and CGI shores within promoters have a very
low basal level of DNA methylation but display enrich-
ment of hydroxymethylation at the island-shore border
(Figure 7A(i)). We propose that hydroxymethylation at
CGI shores establishes a protective boundary for mainten-
ance of methylation-free CGI promoters. Possible mecha-
nisms include creation of a chromatin configuration that
blocks DNMT access, establishment of a zone where any
5mC is rapidly converted to 5hmC, or through an impact
on the binding of boundary factors like CTCF [62]. When
these boundaries become compromised in the absence of
TET (TET downregulation or mutation), either through
loss of 5hmC and/or the chromatin-bound TET proteins
themselves, aberrant CGI shore hypermethylation accumu-
lates and expands throughout the CGI, converting the
transcriptionally permissive state to one that can no longer
respond to stimuli (Figure 7A(ii)). Elucidation of CGIs at
greatest risk for this event might be revealed by depleting
or inhibiting the TETs for a longer time period.
This study also reveals a dynamic interplay between TET
activity and different chromatin marks. Previous work elu-
cidated an association between TET1/5hmC occupancy
and polycomb-/trithorax-mediated histone marks in ESCs
[19-21], but our study is the first to provide a functional
assessment of TET1, TET2, and TET3 activities within
different chromatin domains in cancer cells for which
extensive chromatin mark mapping is also available.
These results indicate two opposing functions for TETs
at H3K4me3-marked promoters and polycomb-marked
(H3K27me3 and H2AK119ub) promoters: removal of
5hmC and enrichment of 5hmC, respectively (Figure 7B).
H3K4me3-marked promoters are enriched for TET1 bin-
ding but are devoid of 5mC or 5hmC [19-21]. H3K4me3-
marks are also characteristic of highly expressed genes and
are typically associated with gene body H3K36me3 enrich-
ment. The results herein reveal that TET2, in particular, is
responsible for eliminating 5hmC at promoters of these
highly expressed, H3K4me3- and H3K36me3-marked loci
(Figure 7B(i)), providing an explanation for the paradoxical
observation that H3K4me3-marked promoters are TET1-
rich but 5hmC-deficient. TET1 was proposed to protect
active H3K4me3 monovalent promoters from aberrant
hypermethylation [19-21]. In our study, however, even with
depletion of TET1, TET2, or TET3, H3K4me3-marked
sites remained protected from DNA hypermethylation,
suggesting that each of the TETs is dispensable for main-
taining hypomethylation at H3K4me3 loci or that there is
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Figure 7 Models for the multi-dimensional functions of TETs in mediating DNA methylation and hydroxymethylation. (A) TET family
members enrich 5hmC at CGI shores to provide a protective boundary against aberrant hypermethylation (i). In the absence of TETs, 5hmC
cannot be established, permitting the aberrant expansion of 5mC into the CGI (ii). (B) In the normal pluripotent state, TETs eliminate 5hmC from
promoters and remove both 5mC and 5hmC from gene bodies of a subset of highly transcriptionally active H3K4me3- and H3K36me3-marked
genes (i). TETs mediate hydroxymethylation and promote a low level of methylation at H3K27me3-marked promoters (ii). At H2AK119ub-marked
promoters TET proteins enrich 5hmC and promote turnover of cytosine modifications by mediating demethylation of 5mC (iii). In the event of
TET mutation or other TET functional disruption (like decreased expression), these distinct epigenetic patterns are lost, making loci vulnerable to
changes in transcriptional activity, perhaps by leaving unmodified cytosines available for aberrant DNA methylation by DNMTs or by permitting
the binding of chromatin remodelers or repressors such as PRC1 or PRC2.
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bivalent promoters showed significant 5hmC loss and gain
in response to depletion of each of the TETs. Interestingly,
bivalent promoters did not significantly accumulate or lose
5mC in response to TET depletion. One possible expla-
nation for this is that TETs stabilize 5hmC (and possibly
the other demethylation intermediates) but do not actively
convert 5mC to 5hmC at bivalent promoters. This is fur-
ther substantiated by unpublished data from our laboratory
that DNMTs have no or low activity at bivalent promoters
in the pluripotent state, suggesting that bivalent promotershave neither a propensity for 5mC accumulation nor a
basis for active demethylation.
Polycomb repressive complex 2 (PRC2) recruits TET1 to
bivalent H3K4me3- and H3K27me3-marked promoters,
which are 5hmC-rich [63]. H2AK119ub- and H3K27me3-
marked promoters showed a disproportionate loss of
5hmC and 5mC under TET knockdown conditions,
suggesting that TET1, TET2, and TET3 establish these
cytosine modifications at polycomb repressed loci, perhaps
as a means of mediating repression of PcG target genes
by supporting 5mC accumulation (Figure 7B(ii,iii)). The
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directly and independently of their catalytic activity by
facilitating a repressive chromatin state. Along these lines,
TET1 recruits SIN3A, a known DNMT3B-interacting
partner, to a subset of TET1 target genes (including
H3K27me3-positive loci), thereby mediating transcriptional
repression and possibly potentiating DNMT3B-dependent
methylation [20,64]. This model is supported by our
laboratory’s observation that TET-depletion-induced hypo-
methylation occurred at a subset of promoters occupied by
DNMT1 or DNMT3B (data not shown), again, pointing to
a role for TETs in facilitating cytosine methylation. Since
many promoters with loss of 5mC also exhibited loss of
5hmC in siTET cells, TETs might promote cytosine me-
thylation through establishment of 5hmC. Intriguingly,
UHRF1 binds 5hmC with high affinity, and UHRF1 is re-
quired for maintenance of DNA methylation by DNMT1
during DNA replication [29,65]; thus, UHRF1 may provide
a mechanistic link in this relationship in that 5hmC accu-
mulation acts not as a precursor for active DNA demethy-
lation, but rather is a signal for de novo DNA methylation.
It will be critical in future experiments to determine the
turnover rate of methyl groups and their derivatives in dif-
ferent chromatin domains of the genome, and correlate
this with the presence or absence of DNMTs and TETs.
Regions may exist where methyl group turnover promotes
DNA demethylation, perhaps due to a lack of DNMTs,
high TET-directed oxidation activity, and/or a particular
combination of histone modifications. Alternatively, loci
may exist where methyl group turnover combined with
high DNMT activity, repressive chromatin signatures, and
as yet uncharacterized TET activities (perhaps independent
of their known catalytic functions), is essential for new or
more extensive DNA methylation marks. If methyl group
turnover is common even in constitutively methylated re-
gions of the genome, then deregulation of any of the steps
in this pathway (DNMTs, TETs, interacting factors, and
substrate availability) could contribute to the hypo- and
hypermethylation events that typify cancer cells.
Our expression analyses revealed both transcriptional
activation and repression events resulting from depletion
of each TET. Other examples of Tet1 depletion in murine
ESCs have demonstrated upregulation and downregula-
tion of target genes, indicating both transcriptional activa-
tion and repression roles for Tet1 [20,59]. In all siTET
depletions, transcriptional repression was significantly
linked with loss of 5hmC at adjacent H3K27ac-marked
enhancers, providing direct evidence that maintenance
of 5hmC in enhancers is required to drive gene expres-
sion, particularly for highly expressed genes. Expression
changes induced by TET deficiency did not show a
clear relationship with promoter methylation changes
(that is, gene repression did not significantly correspond
with promoter hypermethylation). This is not completelyunexpected, given previous studies showing that expres-
sion changes in siTet1-treated DNMT triple knockout
cells, which have no 5mC or 5hmC, were similar to ex-
pression effects in siTet1-treated DNMT wild-type cells,
suggesting that, for some genes, the impact of Tet1 on ex-
pression is independent of its catalytic activity [20] and
may be due to the TET1 protein itself or other uncharac-
terized ‘activities’ of TET1. Thus, we suspect that some of
the expression changes observed in our siTET1-, siTET2-,
and siTET3-treated NCCIT cells (those not accounted
for by 5hmC loss in enhancers) are related to functions
separate from the TET roles in cytosine methylation
patterning described here. The exact nature of these
functions is currently unknown, but might be mediated
through altered 5hmC levels, changes in 5hmC reader
protein localization, or non-enzymatic activities of the
TET proteins. Given the lack of knowledge of TET and
5hmC roles in the genome, cancer-specific TET muta-
tions could potentially be directing pathogenic gene
expression patterns via any of these routes, something
that will be important to examine in future studies.
Nonetheless, a link between 5hmC accumulation and
gene activation was observed during differentiation of
NCCIT cells. Genes with high 5hmC enrichment during
differentiation were often abundantly expressed. This
was especially true for some ectodermal and mesoder-
mal patterning genes, which were enriched with large
peaks of 5hmC during differentiation. Furthermore, genes
that were robustly activated during induction of differenti-
ation also tended to be repressed in TET1, TET2, or
TET3 depleted cells. Taken together, we propose that
TET-mediated enrichment of 5hmC promotes a transcrip-
tionally permissive chromatin environment, and that dis-
ruption of this state represents a crucial step toward
permanent gene silencing by aberrant DNA methylation
in cancer cells.
Conclusions
The recent elucidation of TET hydroxylation activities on
5mC has changed our view of the epigenome from that of
a steady-state methylome to the realization that it is a
dynamic and mutable landscape. The results described
herein establish a compelling framework for how TET-
driven 5hmC patterning impacts gene expression. TET
patterning of the epigenome is clearly a common basis of
both mammalian development and cellular transfor-
mation, and the findings presented here that TETs have
multi-dimensional functions in mediating DNA methyla-
tion, hydroxymethylation, and gene expression patterns is
a crucial step for advancing our mechanistic understan-
ding of how the epigenome functions in both normal and
disease states. Overall, this study expands our knowledge
of how TET dioxygenases impact cytosine modifications
across the cancer genome and reveals that the chromatin
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Materials and methods
Cell culture, siRNA transfections, and extractions
NCCIT cells (from ATCC) and human H9 (WA09) ESCs
were cultured as described [1] and differentiation (NCCIT
cells only) was induced by addition of 10 μM all-trans RA
(Sigma, St. Louis, MO USA) for 7 days. A172 cells (gli-
oma) were obtained from ATCC and cultured in McCoy’s
5a media containing 10% fetal calf serum. On-TARGET-
plus SMARTpools (Dharmacon, Thermo Scientific,
Lafayette, CO USA) composed of a mixture of four indi-
vidual siRNAs targeting a single gene were used against
TET1 (L-014635-02), TET2 (L-013776-03), and TET3
(L-022722-02) in separate experiments. Transfection with
a negative control non-targeting siRNA (D-001206-13-20;
Dharmacon, Thermo Scientific) was performed in parallel.
For siRNA transfections, approximately 4.5 × 104 NCCIT
cells were seeded in each well of a six-well plate. At
24 and 48 hours post-seeding, cells were transfected
using PepMute siRNA transfection reagent (SignaGen,
Rockville, MD USA) prepared according to the manufac-
turer’s protocol. Fresh growth medium (900 μl) was added
to cells 30 minutes prior to addition of 100 μl of transfec-
tion reagent mix. The siRNA transfection mix was com-
posed of 100 μl of PepMute transfection buffer, 1 μl of 40
μM siRNA, and 1.5 μl of PepMute reagent. Fresh media
was added to cells at 72 hours post-seeding, and cells were
harvested at 96 hours post-seeding. Total RNA was
extracted by Trizol homogenization and purified accor-
ding to the manufacturer’s protocols (Life Technologies,
Carlsbad, CA USA). Genomic DNA was extracted by pro-
teinase K digestion and phenol:chloroform extraction as
described [66].
Affinity-based capture of 5hmC and 5mC and sequencing
library preparation
Prior to affinity pull-downs, 5 μg of genomic DNA in 130
μl TE was sheared to less than 400 bp on a Covaris S220
focused-ultrasonicator according to the manufacturer’s in-
structions. Sheared samples were ethanol precipitated and
resuspended in TE to a concentration of approximately
350 ng/μl based on nanodrop spectrophometric measure-
ments. Samples were then normalized to the control sam-
ple by qPCR standard curves. DNA concentrations were
adjusted based on the standard curve. 5hmC enrichment
was performed using 2.5 μg of sheared DNA per reaction
with the Hydroxymethyl Collector kit according to the
manufacturer’s instructions (Active Motif, Carlsbad, CA
USA). Each sample was performed in quadruplicate and
replicates were pooled after the pull-down prior to prepa-
ration of sequencing libraries. Independent 5hmC-capture
experiments were performed for 5hmC-qPCR validationexperiments. Primers for validation qPCR are from [1] or
are listed in Additional file 3. For 5mC-capture, 2 μg of
sheared DNA was used as input for the MethylMagnet
methylated-CpG DNA isolation kit according to the ma-
nufacturer’s instructions (Ribomed, Carlsbad, CA USA)
and reactions were performed in quadruplicate for each
sample. DNA sequencing libraries were generated from
the 5mC and 5hmC captured DNA with the TruSeq
DNA sample preparation kit (Illumina, San Diego, CA
USA) according to manufacturer’s instructions. Agencourt
AMPure XP Beads (Beckman Coulter, Pasadena, CA
USA) used during library preparation were calibrated for
size selection of DNA fragments greater than 200 bp. PCR
amplification of the libraries was performed for 11 cycles.
After PCR amplification, the library was gel purified using
SYBR gold for visualization of DNA, quantified by qPCR
(KAPA Biosystems library quantification kit, Wilmington,
MA USA), and analyzed on a bioanalyzer with a high
sensitivity DNA chip (Agilent, Santa Clara, CA USA) for
quality control and quantification. Libraries were se-
quenced on an Illumina HiSeq2000 (50 bp read length) at
the Tufts University Genomics Core Facility.
Data analysis
Raw sequencing reads were mapped to the UCSC human
genome hg19 build using BWA V0.5.9 [67] with a default
parameter setting. Multiply mapped reads and uniquely
mapped reads with mismatches and indels >5% of read
lengths were filtered out. SICER V1.1 [55] was used to iden-
tify enriched regions (peaks) in a sample and differentially
enriched regions between two samples relative to an input
with the following parameters: redundancy allowed = 1,
window size = 200, fragment size = 300, effective genome
size = 0.854, gap size = 600, E-value = 1,000, false dis-
covery rate = 0.01. In-house scripts annotated peaks and
differentially enriched regions with RefSeq, CGIs, and re-
peats in the UCSC genome browser [68], and classified
them as promoter (-1 kbp to +1 for TSS), body, and 3′
end (TTS + 1 kbp). In some cases, gene bodies were
further classified into 5′ UTR, exon, protein coding exon,
3′ UTR, and intron. Genes were also stratified based on
the CpG density within their promoter regions (HCPs,
intermediate CpG density promoters (ICPs), and LCPs)
using the criteria in [69]. In this classification, HCPs are
‘strong’ CGIs while ICPs are ‘weak’ CGIs. LCPs are a
distinct class. Gene lists in promoters and bodies were
analyzed using in-house scripts via the DAVID server
(default settings) for functional annotation using gene
ontologies and pathways [70]. After discarding more than
two reads mapping to the same location, mapped reads were
lengthened to the 3’ end to reflect their original length, and
counted based on their midpoint for genomic features such
as genes, CGIs, and repeats. A genomic feature was binned
by relative positions including upstream and downstream
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were taken into account by calculating FPKM (fragments
per kilobase per million fragments mapped). To illustrate
the change in tag densities around genes, we used a
relative length window for gene bodies and measured the
average of normalized read coverage in a window.5mC and 5hmC quantification and TAB-seq
DNA methylation and hydroxymethylation quantification
was performed using the MethylFlash methylated and
hydroxymethylated colorimetric DNA quantification kits
(P-1034; p-1036; Epigentek, Farmingdale, NY USA) ac-
cording to the manufacturer’s instructions. All samples
were run in triplicate. TAB conversion of DNA was per-
formed as described [71]. To accommodate for Sanger
sequencing, DNA was sheared with a Covaris S220 to less
than 10 kb in size and purified by ethanol precipitation
prior to TAB conversion. Bisulfite conversion and sequen-
cing of DNA were performed as previously described [1].
Up to 12 independent clones were sequenced for each
region. Primer sequences are listed in Additional file 3.
TAB-seq plots were generated with QUMA [72].Expression analysis by qRT-PCR and microarray
CDNA synthesis, qRT-PCR, and data analysis was per-
formed as described previously [73,74]. qRT-PCR primers
were designed and selected for optimal efficiency based on
their performance with a standard curve of cDNA tem-
plate. qRT-PCR was performed with at least three repli-
cates. Primer sequences are listed in Additional file 3.
Gene expression profiling was performed using Affymetrix
Human Gene 1.0 ST arrays. All samples were analyzed in
duplicate at the Georgia Regents University Cancer Center
Genomics Core facility as described previously [1].Gene ontology analysis and statistical methods for data
set comparisons
Ontology analysis was performed using the functional
annotation tool within the DAVID bioinformatics data-
base [70,75]. Fisher exact test with a two-tailed P-value
calculation was used for testing the significance of data
set comparisons as described previously for similar data
sets [76]. For added stringency, a modified EASE score
was applied to all Fisher exact tests [70,75].Data access
Sequencing and expression microarray data have been
deposited into the NCBI Gene Expression Omnibus
database under accession number GSE51903. Additional
published datasets used in this analysis include: GSM747152,
GSM605307, and GSE38938.Additional files
Additional file 1: Supplementary figures.
Additional file 2: Table S1. Number of differentially methylated genes
stratified by magnitude of methylation change.
Additional file 3: Table S2. PCR primer sequences.
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